ERBB2 and metastatic malignant neoplasm in the lymph nodes: There were significant differences in age, menopause status, lymph node metastasis, and HER2 overexpression for tumor progression (P < 0.05) and Exp (B), namely, 1.08, 4.45, 6.97, and 3.88, respectively.